Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ).
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has received authorization from the European Medicines Agency (EMA) to manufacture enoxaparin sodium injections under the brand name Inhixa. This development marks a significant step in the company’s internationalization strategy, enhancing its market competitiveness in the European Economic Area. The completion of a new pre-filled formulation production line at Hepalink Pingshan Park, with a capacity of 330 million units per year, supports this expansion. The authorization is expected to positively impact the company’s future business growth by facilitating entry into European and American markets.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$3.88 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, focusing on the production of heparin and related products. The company is involved in the manufacture and distribution of pharmaceutical products, with a market focus on expanding its presence in international markets, particularly in Europe and America.
Average Trading Volume: 2,811,983
Technical Sentiment Signal: Buy
Current Market Cap: HK$18.16B
Find detailed analytics on 9989 stock on TipRanks’ Stock Analysis page.